# ALYMSYS

NDC: 70121-1755
Generic name: bevacizumab-maly
Labeler / Manufacturer: Amneal Pharmaceuticals LLC
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: INTRAVENOUS
Marketing started: 20220415
Marketing ended: 20281031
FDA application: BLA761231

## Active ingredients

- BEVACIZUMAB: 400 mg/16mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"70121-1755"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=70121-1755
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b4040a2-a5c5-4ff0-ab45-935d7e49cf78
